Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Forms $150 Million China Immunotherapy Partnership With MacroGenics

publication date: Jul 11, 2019

I-Mab Biopharma, a Shanghai oncology company, in-licensed greater China rights to a novel immunotherapy developed by MacroGenics of Maryland. The candidate, enoblituzumab, is an investigational B7-H3 antibody. A member of the family of B7 immune regulator proteins, B7-H3 is expressed by several types of tumors. I-Mab agreed to a $150 million package of upfront and milestone payments, plus royalties. It will lead greater China trials of the candidate and also participate in MacroGenics global tests, currently testing enoblituzumab in patients with head and neck cancer. More details....

Stock Symbol: (NSDQ: MGNX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.